Detail of "60239-18-1"

Reference

Method for assessing myocardial angiogenesis

Some chemicals with cas registry numbers like 25513-46-6 and 60239-18-1 are also used. Method for assessing myocardial angiogenesis. Uzgiris, Egidijus E. (USA ). U.S. Pat. Appl. Publ. US 2004024318 A1 5 Feb 2004,12 pp. (English). (United States of America). CODEN: USXXCO. CLASS: ICM: A61B005-05. ICS: A61B008-14. NCL: 600458000; 424009510. APPLICATION: US 2002-209989 31 Jul 2002. DOCUMENT TYPE: Patent CA Section: 8 (Radiation Biochemistry) Section cross-reference(s): 63 Polymeric contrast agents are used to monitor myocardial neovascularization. The agent is injected and images of the myocardium are obtained at various time intervals after injection. Localized image enhancement indicates an area of increased angiogenesis. An example of an MRI contrast agent is polylysine-conjugated Gd-DTPA complex. .

Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-epratuzumab): do tumor targeting and dosimetry predict therapeutic response?

Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-epratuzumab): do tumor targeting and dosimetry predict therapeutic response?. Sharkey, Robert M.; Brenner, Arnold; Burton, Jack; Hajjar, George; Toder, Stephen P.; Alavi, Abass; Matthies, Alexander; Tsai, Donald E.; Schuster, Stephen J.; Stadtmauer, Edward A.; Czuczman, Myron S.; Lamonica, Dominick; Kraeber-Bodere, Francoise; Mahe, Beatrice; Chatal, Jean-Francois; Rogatko, Andre; Mardirrosian, George; Goldenberg, David M. (Center for Molecular Medicine and Immunology, Garden State Cancer Center, Belleville, NJ, USA). Journal of Nuclear Medicine, 44(12), 2000-2018 (English) 2003 Society of Nuclear Medicine. CODEN: JNMEAQ. ISSN: 0161-5505. DOCUMENT TYPE: Journal CA Section: 8 (Radiation Biochemistry) Section cross-reference(s): 1, 15 A DOTA (1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid)-conjugated, 111In- and 90Y-labeled humanized antibody to CD22, epratuzumab, was studied in patients with non-Hodgkin's lymphoma (NHL) to assess biodistribution and tumor targeting, pharmacokinetics, dosimetry, and anti-antibody response. Of particular interest was to evaluate whether pre-therapy targeting and tumor dosimetry could predict therapeutic responses. Methods: Patients received a pretherapy imaging study with 111In-DOTA-epratuzumab IgG (0.75 mg/kg), followed about 1 wk later with 90Y-DOTA-epratuzumab starting at a dose level of 0.185 GBq/m2 (5 mCi/m2) in patients who had prior high-dose chemotherapy (group 2), and at 0.370 GBq/m2 in patients who did not have a prior transplant (group 1), with escalation in 0.185-GBq/m2 increments. Results: The effective blood half-life for 111In-DOTA epratuzumab was 36.1 ± 7.9 h (n = 25) compared with 35.2 ± 7.0 h for 90Y-DOTA-epratuzumab (n = 22). The whole-body half-life for 90Y-DOTA-epratuzumab estd. from 111In-DOTA-epratuzumab scintigraphy was 58.3 ± 4.7 h (n = 20), with urine collection confirming the loss of between 2.2% and 15.9% of the injected activity over 3 d (n = 3). One-hundred sixteen of 165 CT-confirmed lesions were visualized with 111In-DOTA-epratuzumab. Radiation-absorbed doses to liver, lungs, and kidneys averaged 0.55 ± 0.13 (n = 17), 0.28 ± 0.06 (n = 17), and 0.38 ± 0. 60239-18-1 and 10098-91-6 are cas registry numbers of chemicals which are used as reagents here.07 mGy/MBq (n = 10), resp., with 0.14 ± 0.02 and 0.23 ± 0.04 mGy/MBq delivered to the whole-body and red marrow, resp. Tumor doses (n = 14 lesions in 10 patients) ranged from 1.0 to as much as 83 mGy/MBq for a 0.5-g lesion (median, 7.15 mGy/MBq). Group 2 patients were more likely to experience significant hematol. toxicities, but doses of up to 0.370 GBq/m2 of 90Y-DOTA-epratuzumab were tolerated with std. support measures, whereas patients in group 1 tolerated doses of up to 0.740 GBq/m2 with the potential for further escalation. Antitumor effects were seen in both indolent and aggressive NHL. The data also suggest that antitumor responses of potentially equal magnitude can occur irresp. of tumor targeting and tumor size. Hence, tumor response did not correlate with the radiation dose delivered or with the tumor being visualized by external imaging. An anti-antibody response to epratuzumab was detected by an ELISA in only 2 of 16 patients. Conclusion: These results suggest that 90Y-DOTA-epratuzumab is a promising agent for the treatment of NHL and warrants further study. There was evidence suggesting that in this system, factors other than tumor radiation dose and targeting may be involved in the success of radioimmunotherapy. .